Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Cited by (1,050)

Items 101–200 of 1,050

1. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer
   Weickhardt, Andrew J., Scheier, Benjamin, Burke, Joseph Malachy, Gan, Gregory, Lu, Xian, Bunn, Paul A., Aisner, Dara L., Gaspar, Laurie E., Kavanagh, Brian D., Doebele, Robert C. et al. · 2012 · Journal of Thoracic Oncology
2. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
   Martin Reck, Sanjay Popat, Niels Reinmuth, Dirk De Ruysscher, Keith M. Kerr, Solange Peters · 2014 · Annals of Oncology
3. State-of-the-art gene-based therapies: the road ahead
   Mark A. Kay · 2011 · Nature Reviews Genetics
4. Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
   Sequist, Lecia V., Soria, Jean-Charles, Goldman, Jonathan W., Wakelee, Heather A., Gadgeel, Shirish M., Varga, Andrea, Papadimitrakopoulou, Vassiliki, Solomon, Benjamin J., Oxnard, Geoffrey R., Dziadziuszko, Rafal et al. · 2015 · New England Journal of Medicine
5. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)
   Dearden, S., Stevens, J., Wu, Y.-L., Blowers, D. · 2013 · Annals of Oncology
6. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
   Christian Diego Rolfo, Philip C. Mack, Giorgio V. Scagliotti, Paul Baas, Fabrice Barlési, Trever Grant Bivona, Roy S. Herbst, Tony S.K. Mok, Nir Peled, Robert Pirker et al. · 2018 · Journal of Thoracic Oncology
7. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
   Jänne, Pasi A, Shaw, Alice T, Pereira, José Rodrigues, Jeannin, Gaëlle, Vansteenkiste, Johan, Barrios, Carlos, Franke, Fabio Andre, Grinsted, Lynda, Zazulina, Victoria, Smith, Paul et al. · 2013 · The Lancet Oncology
8. TRKing Down an Old Oncogene in a New Era of Targeted Therapy
   Aria Vaishnavi, Anh T. Le, Robert Charles Doebele · 2014 · Cancer Discovery
9. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
   Jacob J. Chabon, Andrew D. Simmons, Alexander F. Lovejoy, Mohammad Shahrokh Esfahani, Aaron M. Newman, Henry J. Haringsma, David Matthew Kurtz, Henning Stehr, Florian Scherer, Chris Karlovich et al. · 2016 · Nature Communications
10. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
    Niederst, Matthew J., Sequist, Lecia V., Poirier, John T., Mermel, Craig H., Lockerman, Elizabeth L., Garcia, Angel R., Katayama, Ryohei, Costa, Carlotta, Ross, Kenneth N., Moran, Teresa et al. · 2015 · Nature Communications
11. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
    Glenwood D. Goss, Chun‐Ming Tsai, Frances A. Shepherd, Lyudmila A. Bazhenova, Jong Seok Lee, Gee‐Chen Chang, Lucio Crinò, Miyako Satouchi, Quincy Siu-Chung Chu, Toyoaki Hida et al. · 2016 · The Lancet Oncology
12. The emerging clinical relevance of genomics in cancer medicine
    Michael F. Berger, Elaine R. Mardis · 2018 · Nature Reviews Clinical Oncology
13. Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation
    Oxnard, Geoffrey R., Arcila, Maria E., Sima, Camelia S., Riely, Gregory J., Chmielecki, Juliann, Kris, Mark G., Pao, William, Ladanyi, Marc, Miller, Vincent A. · 2011 · Clinical Cancer Research
14. Molecular analysis of circulating tumour cells—biology and biomarkers
    Matthew Krebs, Robert Lewin Metcalf, Louise Carter, Gerard Brady, Fiona Helen Blackhall, Caroline Dive · 2014 · Nature Reviews Clinical Oncology
15. Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
    Walter, Annette O., Sjin, Robert Tjin Tham, Haringsma, Henry J., Ohashi, Kadoaki, Sun, Jing, Lee, Kwangho, Dubrovskiy, Aleksandr, Labenski, Matthew, Zhu, Zhendong, Wang, Zhigang et al. · 2013 · Cancer Discovery
16. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
    Peter T. Harrison, Simon Vyse, Paul H. Huang · 2019 · Seminars in Cancer Biology
17. The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
    Hata, Aaron N., Engelman, Jeffrey A., Faber, Anthony C. · 2015 · Cancer Discovery
18. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
    Aria Vaishnavi, Marzia Capelletti, Anh Tuan Le, Severine L. Kako, Mohit Butaney, Dalia Ercan, Sakshi Mahale, Kurtis D. Davies, Dara L. Aisner, Amanda B. Pilling et al. · 2013 · Nature Medicine
19. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications
    Yasuda, Hiroyuki, Kobayashi, Susumu, Costa, Daniel B · 2012 · The Lancet Oncology
20. Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling
    Hirata, Eishu, Girotti, Maria Romina, Viros, Amaya, Hooper, Steven, Spencer-Dene, Bradley, Matsuda, Michiyuki, Larkin, James, Marais, Richard, Sahai, Erik · 2015 · Cancer Cell
21. EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance
    Uribe, Mary Luz, Marrocco, Ilaria, Yarden, Yosef · 2021 · Cancers
22. New Pathologic Classification of Lung Cancer: Relevance for Clinical Practice and Clinical Trials
    William David Travis, Elisabeth M. Brambilla, Gregory J. Riely · 2013 · Journal of Clinical Oncology
23. CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
    Daniel Botelho Costa, Susumu S. Kobayashi, Shuchi Sumant Pandya, Wee-Lee Yeo, Zhongzhou Shen, Weiwei Tan, Keith D. Wilner · 2011 · Journal of Clinical Oncology
24. Circulating tumor DNA and liquid biopsy in oncology
    Cescon, David W., Bratman, Scott V., Chan, Steven M., Siu, Lillian L. · 2020 · Nature Cancer
25. A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
    Takaaki Sasaki, Jussi Pekka Koivunen, Atsuko Ogino, Masahiko Yanagita, Sarah Nikiforow, Wei Zheng, Christopher S. Lathan, J. Paul Marcoux, Jinyan Du, Katsuhiro Okuda et al. · 2011 · Cancer Research
26. Non-small-cell lung cancer
    Lizza E.L. Hendriks, Jordi Remón, Corinne Faivre Finn, Marina Chiara Garassino, John Victor Heymach, Keith M. Kerr, Daniel S.W. Tan, Giulia Veronesi, Martin Reck · 2024 · Nature Reviews Disease Primers
27. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
    Armida D’Incecco, Mariacarla Andreozzi, Vienna Ludovini, Elisa Rossi, Alessandra Capodanno, Lorenza Maria Landi, Carmelo Tibaldi, Gabriele Minuti, Jessica Salvini, Erika Coppi et al. · 2014 · British Journal of Cancer
28. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt
    Patrick J Royston, Mahesh Parmar · 2011 · Statistics in Medicine
29. The transcriptional landscape and mutational profile of lung adenocarcinoma
    Jeong‐Sun Seo, Young Seok Ju, Won‐Chul Lee, Jong-Yeon Shin, Jake June-Koo Lee, Thomas Bleazard, Junho Lee, Yoo Jin Jung, Jung Oh Kim, Jung-Young Shin et al. · 2012 · Genome Research
30. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
    Niederst, Matthew J., Hu, Haichuan, Mulvey, Hillary E., Lockerman, Elizabeth L., Garcia, Angel R., Piotrowska, Zofia, Sequist, Lecia V., Engelman, Jeffrey A. · 2015 · Clinical Cancer Research
31. A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC
    Lisberg, A., Cummings, A., Goldman, J.W., Bornazyan, K., Reese, N., Wang, T., Coluzzi, P., Ledezma, B., Mendenhall, M., Hunt, J. et al. · 2018 · Journal of Thoracic Oncology
32. Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
    Arcila, Maria E., Oxnard, Geoffrey R., Nafa, Khedoudja, Riely, Gregory J., Solomon, Stephen B., Zakowski, Maureen F., Kris, Mark G., Pao, William, Miller, Vincent A., Ladanyi, Marc · 2011 · Clinical Cancer Research
33. Overcoming therapy resistance in EGFR-mutant lung cancer
    Passaro, Antonio, Jänne, Pasi A., Mok, Tony, Peters, Solange · 2021 · Nature Cancer
34. Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
    Yasuda, Hiroyuki, Park, Eunyoung, Yun, Cai-Hong, Sng, Natasha J., Lucena-Araujo, Antonio R., Yeo, Wee-Lee, Huberman, Mark S., Cohen, David W., Nakayama, Sohei, Ishioka, Kota et al. · 2013 · Science Translational Medicine
35. Precision medicine for cancer with next-generation functional diagnostics
    Friedman, Adam A., Letai, Anthony, Fisher, David E., Flaherty, Keith T. · 2015 · Nature Reviews Cancer
36. The biology and treatment of EML4-ALK non-small cell lung cancer
    Takaaki Sasaki, Scott J. Rodig, Lucian R. Chirieac, Pasi Antero Janne · 2010 · European Journal of Cancer
37. Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
    Suresh S. Ramalingam, James Chih‐Hsin Yang, Chee Khoon Lee, Takayasu Kurata, Dong‐Wan Kim, Thomas John, Naoyuki Nogami, Yuichiro Ohe, Helen Mann, Yuri Rukazenkov et al. · 2017 · Journal of Clinical Oncology
38. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
    Ryohei Katayama, Tahsin M. Khan, Cyril H. Benes, Eugene Lifshits, Hiromichi Ebi, Victor M. Rivera, William C. Shakespeare, Anthony John Iafrate, Jeffrey A. Engelman, Alice Tsang Shaw · 2011 · Proceedings of the National Academy of Sciences
39. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
    Inoue, A., Kobayashi, K., Maemondo, M., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I. et al. · 2013 · Annals of Oncology
40. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
    Wen‐Zhao Zhong, Qun Wang, Weimin Mao, Lin Xu, Lin Wu, Yi Shen, Yu Liu, Chun Chen, Ying Cheng, Lin Xu et al. · 2017 · The Lancet Oncology
41. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
    Paz-Ares, L., Tan, E.-H., O’Byrne, K., Zhang, L., Hirsh, V., Boyer, M., Yang, J.C.-H., Mok, T., Lee, K.H., Lu, S. et al. · 2017 · Annals of Oncology
42. Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling
    Juliann Chmielecki, Jasmine Foo, Geoffrey R. Oxnard, Katherine E. Hutchinson, Kadoaki Ohashi, Romel Somwar, Lu Wang, Katherine R. Amato, Maria E. Arcila, Martin L. Sos et al. · 2011 · Science Translational Medicine
43. Pathology of Lung Cancer
    William David Travis · 2011 · Clinics in Chest Medicine
44. Circumventing cancer drug resistance in the era of personalized medicine
    Garraway, Levi A., Jänne, Pasi A. · 2012 · Cancer Discovery
45. Genotyping and Genomic Profiling of Non–Small-Cell Lung Cancer: Implications for Current and Future Therapies
    Tianhong Li, Hsing‐Jien Kung, Philip C. Mack, David R. Gandara · 2013 · Journal of Clinical Oncology
46. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
    Alissa Jamie Cooper, Lecia Van Dam Sequist, Jessica J. Lin · 2022 · Nature Reviews Clinical Oncology
47. Prognosis research strategy (PROGRESS) 4: Stratified medicine research
    Aroon Dinesh Hingorani, Daniëlle van der Windt, Richard D Riley, Keith R. Abrams, Karel G.M. Moons, Ewout Willem Steyerberg, Sara Schroter, Willi Sauerbrei, Douglas G. Altman, Harry Hemingway et al. · 2013 · BMJ
48. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
    Lynn T. Tanoue · 2010 · Yearbook of Pulmonary Disease
49. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC
    D. Ross Camidge, Robert Charles Doebele, Keith M. Kerr · 2019 · Nature Reviews Clinical Oncology
50. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
    Johan Vansteenkiste, Byoung Chul Cho, Tõnu Vanakesa, Tommaso Martino De Pas, Marcin Zielinski, Moon Soo Kim, Jacek Jassem, Masahiro Yoshimura, Jubrail Dahabreh, Haruhiku Nakayama et al. · 2016 · The Lancet Oncology
51. Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis
    Chee Khoon Lee, Chris S. B. Brown, Richard J. Gralla, Vera Hirsh, Sumitra Thongprasert, Chun‐Ming Tsai, Eng Huat Tan, Jcm Ho, D. Chu, Adel Zaatar et al. · 2013 · JNCI Journal of the National Cancer Institute
52. Pretreatment Epidermal Growth Factor Receptor ( EGFR ) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer
    Su, Kang-Yi, Chen, Hsuan-Yu, Li, Ker-Chau, Kuo, Min-Liang, Yang, James Chih-Hsin, Chan, Wing-Kai, Ho, Bing-Ching, Chang, Gee-Chen, Shih, Jin-Yuan, Yu, Sung-Liang et al. · 2012 · Journal of Clinical Oncology
53. Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials
    Maria Clemence Schwaederle, Melissa M. Zhao, J. Jack Lee, Alexander M.M. Eggermont, Richard L. Schilsky, John M. Mendelsohn, Vladimir Lazar, Razelle Kurzrock · 2015 · Journal of Clinical Oncology
54. Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway
    Kurppa, Kari J., Liu, Yao, To, Ciric, Zhang, Tinghu, Fan, Mengyang, Vajdi, Amir, Knelson, Erik H., Xie, Yingtian, Lim, Klothilda, Cejas, Paloma et al. · 2020 · Cancer Cell
55. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial
    Douillard, Jean-Yves, Shepherd, Frances A., Hirsh, Vera, Mok, Tony, Socinski, Mark A., Gervais, Radj, Liao, Mei-Lin, Bischoff, Helge, Reck, Martin, Sellers, Mark V. et al. · 2010 · Journal of Clinical Oncology
56. Intratumor Heterogeneity: Seeing the Wood for the Trees
    Timothy Anthony Yap, Marco Gerlinger, P. Andrew Futreal, Lajos Pusztai, Charles Swanton · 2012 · Science Translational Medicine
57. Non–Small Cell Lung Cancer, Version 6.2015
    Ettinger, David S., Wood, Douglas E., Akerley, Wallace, Bazhenova, Lyudmila A., Borghaei, Hossein, Camidge, David Ross, Cheney, Richard T., Chirieac, Lucian R., D’Amico, Thomas A., Demmy, Todd L. et al. · 2015 · Journal of the National Comprehensive Cancer Network
58. Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component
    Yang, James Chih-Hsin, Ahn, Myung-Ju, Kim, Dong-Wan, Ramalingam, Suresh S., Sequist, Lecia V., Su, Wu-Chou, Kim, Sang-We, Kim, Joo-Hang, Planchard, David, Felip, Enriqueta et al. · 2017 · Journal of Clinical Oncology
59. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
    Alexander Edward Dela Cruz Drilon, Natasha Rekhtman, Maria E. Arcila, Lu Wang, Ai Ni, Melanie Albano, Martine van Voorthuysen, Romel Somwar, Roger S. Smith, Joseph Montecalvo et al. · 2016 · The Lancet Oncology
60. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy
    Vicki Leigh Keedy, Sarah Temin, Mark R. Somerfield, Mary Beth Beasley, David H. Johnson, Lisa M. McShane, Daniel T. Milton, John R. Strawn, Heather A. Wakelee, Giuseppe Giaccone · 2011 · Journal of Clinical Oncology
61. Mechanisms of resistance to EGFR-targeted drugs: lung cancer
    Morgillo, Floriana, Della Corte, Carminia Maria, Fasano, Morena, Ciardiello, Fortunato · 2016 · ESMO Open
62. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study
    Yukio Hosomi, Satoshi Morita, Shunichi Sugawara, Terufumi Kato, Tatsuro Fukuhara, Akihiko Gemma, Kazuhisa Takahashi, Yuka Fujita, Toshiyuki Harada, Koichi Minato et al. · 2019 · Journal of Clinical Oncology
63. Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
    Peter S. Hammerman, Martin L. Sos, Alex H. Ramos, Chunxiao Xu, Amit Dutt, Wenjun Zhou, Lear E. Brace, Brittany A. Woods, Wenchu Lin, Jianming Zhang et al. · 2011 · Cancer Discovery
64. Synthetic lethality as an engine for cancer drug target discovery
    Alan Huang, Levi A. Garraway, Alan Ashworth, Barbara L. Weber · 2019 · Nature Reviews Drug Discovery
65. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
    Garassino, Marina Chiara, Martelli, Olga, Broggini, Massimo, Farina, Gabriella, Veronese, Silvio, Rulli, Eliana, Bianchi, Filippo, Bettini, Anna, Longo, Flavia, Moscetti, Luca et al. · 2013 · The Lancet Oncology
66. Twenty years post‐NIH Revitalization Act: Enhancing minority participation in clinical trials (EMPaCT): Laying the groundwork for improving minority clinical trial accrual
    Moon S. Chen, Primo N. Lara, Julie H. T. Dang, Debora A. Paterniti, Karen L. Kelly · 2014 · Cancer
67. Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
    Mok, Tony, Wu, Yi-Long, Lee, Jin Soo, Yu, Chong-Jen, Sriuranpong, Virote, Sandoval-Tan, Jennifer, Ladrera, Guia, Thongprasert, Sumitra, Srimuninnimit, Vichien, Liao, Meilin et al. · 2015 · Clinical Cancer Research
68. Lung cancer: New biological insights and recent therapeutic advances
    Suresh S. Ramalingam, Taofeek Kunle Owonikoko, Fadlo Raja Khuri · 2011 · CA A Cancer Journal for Clinicians
69. Human organ chip models recapitulate orthotopic lung cancer growth, therapeutic responses, and tumor dormancy in vitro
    Hassell, Bryan A., Goyal, Girija, Lee, Esak, Sontheimer-Phelps, Alexandra, Levy, Oren, Chen, Christopher S., Ingber, Donald E. · 2017 · Cell Reports
70. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
    Zhou, C., Wu, Y.L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S. et al. · 2015 · Annals of Oncology
71. Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer
    Wu, Jenn-Yu, Yu, Chong-Jen, Chang, Yeun-Chung, Yang, Chih-Hsin, Shih, Jin-Yuan, Yang, Pan-Chyr · 2011 · Clinical Cancer Research
72. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease
    Ohashi, Kadoaki, Maruvka, Yosef E., Michor, Franziska, Pao, William · 2013 · Journal of Clinical Oncology
73. ALK in Lung Cancer: Past, Present, and Future
    Alice Tsang Shaw, Jeffrey A. Engelman · 2013 · Journal of Clinical Oncology
74. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
    Liling Huang, Shiyu Jiang, Yuankai Shi · 2020 · Journal of Hematology & Oncology
75. Institutional implementation of clinical tumor profiling on an unselected cancer population
    Sholl, Lynette M., Do, Khanh, Shivdasani, Priyanka, Cerami, Ethan, Dubuc, Adrian M., Kuo, Frank C., Garcia, Elizabeth P., Jia, Yonghui, Davineni, Phani, Abo, Ryan P. et al. · 2016 · JCI Insight
76. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors
    Neal Ian Lindeman, Philip T. Cagle, Mary Beth Beasley, Dhananjay Arun Chitale, Sanja Đačić, Giuseppe Giaccone, Robert Brian Jenkins, David J. Kwiatkowski, Juan‐Sebastian Saldivar, Jeremy Andrew Squire et al. · 2013 · Journal of Molecular Diagnostics
77. Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
    Nasser H. Hanna, Bryan James Schneider, Sarah Temin, Sherman Baker, Julie Renee Brahmer, Peter M. Ellis, Laurie E. Gaspar, Rami Y. Haddad, Paul Joseph Hesketh, Dharamvir Jain et al. · 2020 · Journal of Clinical Oncology
78. Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
    Planchard, David, Kim, Tae Min, Mazieres, Julien, Quoix, Elisabeth, Riely, Gregory, Barlesi, Fabrice, Souquet, Pierre-Jean, Smit, Egbert F, Groen, Harry J M, Kelly, Ronan J et al. · 2016 · The Lancet Oncology
79. Challenges and Opportunities in Cancer Drug Resistance
    Richard A. Ward, Stephen E. Fawell, Nicolas Floc’h, Vikki Flemington, Darren McKerrecher, Paul D. Smith · 2020 · Chemical Reviews
80. Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status
    Douillard, Jean-Yves, Ostoros, Gyula, Cobo, Manuel, Ciuleanu, Tudor, Cole, Rebecca, McWalter, Gael, Walker, Jill, Dearden, Simon, Webster, Alan, Milenkova, Tsveta et al. · 2014 · Journal of Thoracic Oncology
81. PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations
    Filip Jankú, Jennifer J. Wheler, Shannon Neville Westin, Stacy Moulder, Aung Naing, Apostolia Maria Tsimberidou, Siqing Fu, Gerald Steven Falchook, David S. Hong, Ignacio Garrido‐Laguna et al. · 2012 · Journal of Clinical Oncology
82. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
    Chen, Zhao, Cheng, Katherine, Walton, Zandra, Wang, Yuchuan, Ebi, Hiromichi, Shimamura, Takeshi, Liu, Yan, Tupper, Tanya, Ouyang, Jing, Li, Jie et al. · 2012 · Nature
83. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC
    Alex Y. Chang · 2010 · Lung Cancer
84. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations
    Mok, Tony S., Cheng, Ying, Zhou, Xiangdong, Lee, Ki Hyeong, Nakagawa, Kazuhiko, Niho, Seiji, Lee, Min, Linke, Rolf, Rosell, Rafael, Corral, Jesus et al. · 2018 · Journal of Clinical Oncology
85. EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer
    Dong, Zhong-Yi, Zhang, Jia-Tao, Liu, Si-Yang, Su, Jian, Zhang, Chao, Xie, Zhi, Zhou, Qing, Tu, Hai-Yan, Xu, Chong-Rui, Yan, Li-Xu et al. · 2017 · OncoImmunology
86. Validation of the IASLC/ATS/ERS Lung Adenocarcinoma Classification for Prognosis and Association with EGFR and KRAS Gene Mutations: Analysis of 440 Japanese Patients
    Akihiko Yoshizawa, Shinji Sumiyoshi, Makoto Sonobe, Masashi Kobayashi, Masakazu Fujimoto, Fumi Kawakami, Tatsuaki Tsuruyama, William David Travis, Hiroshi Date, Hironori Haga · 2012 · Journal of Thoracic Oncology
87. Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer
    Lecia Van Dam Sequist, Benjamin Besse, Thomas James Lynch, Vincent A. Miller, Kwok‐Kin Wong, Barbara Jennifer Gitlitz, Keith D. Eaton, Charles Zacharchuk, Amy Freyman, Christine Powell et al. · 2010 · Journal of Clinical Oncology
88. Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
    Ken Uchibori, Naohiko Inase, Mitsugu Araki, Mayumi Kamada, Shigeo Sato, Yasushi Okuno, Naoya Fujita, Ryohei Katayama · 2017 · Nature Communications
89. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
    Neal Ian Lindeman, Philip T. Cagle, Mary Beth Beasley, Dhananjay Arun Chitale, Sanja Đačić, Giuseppe Giaccone, Robert Brian Jenkins, David J. Kwiatkowski, Juan‐Sebastian Saldivar, Jeremy Andrew Squire et al. · 2013 · Archives of Pathology & Laboratory Medicine
90. A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK -Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry
    Mari A. Mino-Kenudson, Lucian R. Chirieac, Kenny Law, Jason L. Hornick, Neal Ian Lindeman, Eugene Jerome Mark, David Cohen, Bruce Evan Johnson, Pasi Antero Janne, Anthony John Iafrate et al. · 2010 · Clinical Cancer Research
91. Tumor Microenvironment and Differential Responses to Therapy
    Hirata, Eishu, Sahai, Erik · 2017 · Cold Spring Harbor Perspectives in Medicine
92. Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib
    Vince D. Cataldo, Don Lynn Gibbons, Roman Perez-Soler, Alfonso Quintás‐Cardama · 2011 · New England Journal of Medicine
93. Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR -Mutated Lung Cancer
    Vanita Noronha, Vijay Patil, Amit Joshi, Nandini Sharrel Menon, Anuradha Chougule, Abhishek Mahajan, Amit Janu, Nilendu C. Purandare, Rajiv Kumar, Sucheta Bhagwan More et al. · 2019 · Journal of Clinical Oncology
94. Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy
    Kobayashi, Yoshihisa, Mitsudomi, Tetsuya · 2016 · Cancer Science
95. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
    Douillard, J-Y, Ostoros, G, Cobo, M, Ciuleanu, T, McCormack, R, Webster, A, Milenkova, T · 2014 · British Journal of Cancer
96. Diagnosis of Lung Cancer in Small Biopsies and Cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification
    William David Travis, Elisabeth M. Brambilla, Masayuki Noguchi, Andrew Gordon Nicholson, Kim R. Geisinger, Yasushi Yatabe, Yuichi Ishikawa, Ignacio Ivan Wistuba, Douglas B. Flieder, Wilbur A. Franklin et al. · 2012 · Archives of Pathology & Laboratory Medicine
97. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
    Roy S. Herbst, Yan Ping Sun, Wilfried Eberhardt, Paul R. Germonpré, Nagahiro Saijo, Caicun Zhou, Jie Wang, Longyun Li, Fairooz F. Kabbinavar, Yukito Ichinose et al. · 2010 · The Lancet Oncology
98. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
    Alexander Edward Dela Cruz Drilon, Zishuo I. Hu, Gillianne Geet Yi Lai, Daniel S.W. Tan · 2017 · Nature Reviews Clinical Oncology
99. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
    Soria, Jean-Charles, Wu, Yi-Long, Nakagawa, Kazuhiko, Kim, Sang-We, Yang, Jin-Ji, Ahn, Myung-Ju, Wang, Jie, Yang, James Chih-Hsin, Lu, You, Atagi, Shinji et al. · 2015 · The Lancet Oncology
100. The IASLC Lung Cancer Staging Project
     Wilfried Eberhardt, Alan Mitchell, John J. Crowley, Haruhiko Kondo, Young Tae Kim, Andrew T. Turrisi, Peter G. Goldstraw, Ramón Rami–Porta · 2015 · Journal of Thoracic Oncology